SAB Biotherapeutics SABS
NASDAQ SABS
$3.11 +0.04 (+1.30%)
At close: Nov 11, 2026 · 4:00 PM EST

SAB Biotherapeutics (SABS) Long-Term Debt Issuances (2020 - 2021)

Updated

SAB Biotherapeutics' Long-Term Debt Issuances came in at $515,986 for FY2024, down 32.6% from $765,194 in FY2023.

Analysis

SAB Biotherapeutics (SABS) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends

Going back to FY2021, SAB Biotherapeutics' Long-Term Debt Issuances data covers 4 years.

  • Long-Term Debt Issuances has declined in each of the last three years, with a three-year compound annual growth rate of -43.4% (FY2021 to FY2024).
  • Per Business Quant, earlier years put Long-Term Debt Issuances at $765,194 in FY2023 (-38.1%), $1.24 million in FY2022 (-56.5%) and $2.84 million in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Issuance (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 9.98 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 SAB Biotherapeutics 279.79 Mn -130.87 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -1.38 Mn
Jun 30, 2021 4.07 Mn
Mar 31, 2021 150,000.00
Dec 31, 2020 150,000.00
API Access

SAB Biotherapeutics Long-Term Debt Issuances API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-issuances&ticker=SABS&period=max&api_key=YOUR_API_KEY